Goldman Sachs raises Thermo Fisher Scientific price target to USD 780

Goldman Sachs has raised its price target for Thermo Fisher Scientific (ISIN US8835561023) from USD 650.00 to USD 780.00, as announced on September 21, 2026. This adjustment comes as the stock was trading at EUR 607.80 on October 6, 2026, at Lang & Schwarz, marking a 1.22% increase from the prior close of EUR 600.50.

The move follows Thermo Fisher's strong second-quarter performance in 2026, with revenue reaching USD 11.99 billion, a 10% increase from the same period last year. Adjusted earnings per share rose by 13% to USD 6.03, while adjusted operating income increased by 15% to USD 2.73 billion. The company's adjusted operating margin also improved to 22.8% from 21.9% a year earlier. GAAP diluted earnings per share saw a 9% increase to USD 4.68.

In the second-quarter earnings call, Thermo Fisher raised its 2026 revenue guidance to USD 47.40 billion-USD 48.10 billion and adjusted earnings-per-share guidance to USD 24.93-USD 25.33. The midpoint of the adjusted earnings range increased by USD 0.25 from the previous outlook, though the guidance still accounts for the expected impact of the microbiology divestiture.

The next earnings report is scheduled for October 28, 2026, before the market opens. This report will be a key checkpoint for investors to assess whether the second-quarter improvements and the higher full-year outlook are sustainable. As of October 5, 2026, Thermo Fisher Scientific's market capitalization stood at USD 250.2 billion, with a 52-week range of USD 435.27-USD 683.63.